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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
glomerulo nephritis (MPGN) type I. 
They identified a high prevalence of 
abnormalities of the alternative com-
plement pathway in these diseases that 
included genetic mutation of comple-
ment genes and acquired abnormalities 
of complement regulation. These studies 
contribute important new information 
regarding the prognosis and pathogen-
esis of complement-mediated kidney 
diseases. See pages 454 and 465.
Microvesicles  
protect from acute 
kidney injury
Endothelial progenitor cells (EPCs) are 
circulating bone marrow–derived cells 
that traffic to sites of injury and limit 
damage to organs, including the kidney, 
in experimental models. The protective 
effects of EPCs have been attributed, in 
part, to release of microvesicles (MVs), 
Complement 
abnormalities in 
glomerular disease
Dysregulated activation of the alter-
native pathway of complement causes 
kidney diseases, including C3 glomeru-
lonephritis (C3GN) and dense deposit 
disease (DDD). Though there has been 
excitement in the nephrology commu-
nity because recent studies have dem-
onstrated that complement inhibitors 
might be efficacious in treating these 
diseases, the clinical presentation, prog-
nosis, and pathogenesis of these diseases 
remain incompletely understood. In 
this issue, Sethi et al. extensively char-
acterize the pathologic findings and 
clinical course of a cohort of patients 
with C3GN. Importantly, they also use 
proteinomic techniques to identify the 
proteins that become deposited in the 
glomeruli in these diseases. In a separate 
paper, Servais and colleagues describe 
a cohort of patients with DDD, C3GN, 
and primary membranoproliferative 
which may contain RNA, protein, and/or 
other molecules. Cantaluppi et al. report 
elegant studies demonstrating that intra-
venous injection of MVs protects mice 
from renal ischemia–reperfusion injury 
and that this protection is dependent on 
the presence of microRNAs contained 
within MVs. See page 412.
Aging alters risk  
of death versus  
end-stage renal 
disease in chronic 
kidney disease
As patients develop worsening chronic 
kidney disease (CKD), their risk of mor-
tality and their risk of end-stage renal 
disease (ESRD) both increase. However, 
it is not clear how age affects the rela-
tive likelihood of these competing risks. 
In this issue, De Nicola and colleagues 
examine the effect of age on the risk of 
mortality versus ESRD in a cohort of 
patients with stage 3–5 CKD. Patients 
younger than 60 were more likely to 
develop ESRD than to die at all CKD 
stages, but the relative risk of mortal-
ity increased with age so that by age 85, 
only patients with an estimated glomer-
ular filtration rate less than 15 ml/min 
were at greater risk of ESRD than death. 
These prognostic data are important for 
clinicians who care for elderly patients 
with CKD. See page 482.
